A Phase 1 Study of the Relative Bioavailability of Two PRN1008 Tablet Formulations, Effect of PRN1008 on Midazolam Pharmacokinetics, and Impact of Famotidine on PRN1008 Pharmacokinetics in Healthy Subjects

Trial Profile

A Phase 1 Study of the Relative Bioavailability of Two PRN1008 Tablet Formulations, Effect of PRN1008 on Midazolam Pharmacokinetics, and Impact of Famotidine on PRN1008 Pharmacokinetics in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 03 May 2018

At a glance

  • Drugs PRN 1008 (Primary) ; Famotidine; Midazolam
  • Indications Autoimmune disorders; Idiopathic thrombocytopenic purpura; Pemphigus vulgaris
  • Focus Pharmacokinetics
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 30 Apr 2018 Status changed from not yet recruiting to completed.
    • 19 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top